Search Results
10
Everything
Jubilant DraxImage receives approval from Health Canada for the RUBY Elution System™ (RbES) and proprietary RUBY™ Consumable Accessories
October 13, 2017 11:29 ET
|
Jubilant DraxImage
Montreal, QC, Oct. 13, 2017 (GLOBE NEWSWIRE) -- Jubilant DraxImage Inc. (“DraxImage”), a Jubilant Pharma whollyowned subsidiary, is pleased to announce it has received approval from Health Canada...

Chelsea Therapeutics to Present At the Rodman and Renshaw 10th Annual Healthcare Conference On Monday, November 10, 2008
October 30, 2008 07:30 ET
|
Chelsea Therapeutics
CHARLOTTE, N.C., Oct. 30, 2008 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the Rodman & Renshaw 10th Annual Healthcare Conference at 3:40...

Chelsea Therapeutics to Present At the UBS Global Life Sciences Conference On Monday, September 22, 2008
September 16, 2008 07:30 ET
|
Chelsea Therapeutics
CHARLOTTE, N.C., Sept. 16, 2008 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the UBS Global Life Sciences Conference at 11:00 AM on Monday,...
Antisoma Announces Promising Preliminary Phase II Data for AS1404 in Lung Cancer
October 17, 2005 02:19 ET
|
Antisoma plc
LONDON, Oct. 17, 2005 (PRIMEZONE) -- Cancer drug developer Antisoma (LSE:ASM) today announces preliminary findings from an ongoing phase II trial of AS1404 in lung cancer. With initial data...
Crucell Announces Evaluation by Genentech of STAR(TM) Technology
January 07, 2005 02:08 ET
|
Crucell N.V.
LEIDEN, The Netherlands, Jan. 7, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) announced today that Genentech, Inc. (NYSE:DNA) is currently evaluating...